3-V Biosciences, Inc., a Menlo Park, California-based biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious disease, completed a $20m Series C financing round.
Backers included existing investors Kleiner Perkins Caufield & Byers and New Enterprise Associates.
Led by Merdad Parsey, M.D., Ph.D., Chief Executive Officer, 3-V Biosciences discovers and develops therapeutics that modulate key pathways in oncology and infectious disease.
In oncology, its lead candidate is a fatty acid synthase (FASN) inhibitor that blocks tumor cell signaling pathways and induces tumor cell apoptosis.
IN addition, it is currently evaluating antiviral therapeutic candidates for respiratory syncytial virus (RSV), herpes simplex virus (HSV) and hepatitis C virus (HCV).
It now intends to use the funds to advance its lead oncology candidate into a Phase 1 clinical trial and to conduct ongoing preclinical studies of multiple virology leads generated by its integrated drug discovery process.
FinSMEs
22/06/2013